| Literature DB >> 35256775 |
Lei-Lei Chen1,2, Carmen Morcelle1, Zhou-Li Cheng1, Xiufei Chen1, Yanping Xu2, Yajing Gao1,3, Junbin Song1, Zhijun Li2, Matthew D Smith2, Miao Shi4, Yezhang Zhu4, Neng Zhou5, Meng Cheng2, Chenxi He1, Kwei-Yan Liu1,3, Guoping Lu6, Lei Zhang1, Cheng Zhang1, Jinye Zhang1, Yiping Sun1, Tuan Qi7, Yingying Lyu8, Zhi-Zhong Ren2, Xian-Ming Tan2, Jiayong Yin1, Fei Lan1, Ying Liu9, Hui Yang8, Maoxiang Qian1,10, Caiwen Duan5, Xing Chang7, Yufeng Zhou1,3, Li Shen4, Albert S Baldwin2, Kun-Liang Guan11, Yue Xiong2,12,13, Dan Ye14.
Abstract
As one of the most induced genes in activated macrophages, immune-responsive gene 1 (IRG1) encodes a mitochondrial metabolic enzyme catalysing the production of itaconic acid (ITA). Although ITA has an anti-inflammatory property, the underlying mechanisms are not fully understood. Here we show that ITA is a potent inhibitor of the TET-family DNA dioxygenases. ITA binds to the same site on TET2 as the co-substrate α-ketoglutarate, inhibiting TET2 catalytic activity. Lipopolysaccharide treatment, which induces Irg1 expression and ITA accumulation, inhibits Tet activity in macrophages. Transcriptome analysis reveals that TET2 is a major target of ITA in suppressing lipopolysaccharide-induced genes, including those regulated by the NF-κB and STAT signalling pathways. In vivo, ITA decreases the levels of 5-hydroxymethylcytosine, reduces lipopolysaccharide-induced acute pulmonary oedema as well as lung and liver injury, and protects mice against lethal endotoxaemia, depending on the catalytic activity of Tet2. Our study thus identifies ITA as an immune modulatory metabolite that selectively inhibits TET enzymes to dampen the inflammatory responses.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35256775 PMCID: PMC9305987 DOI: 10.1038/s41556-022-00853-8
Source DB: PubMed Journal: Nat Cell Biol ISSN: 1465-7392 Impact factor: 28.213